Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Efentakis P, Varela A, Chavdoula E, Sigala F, Sanoudou D, Tenta R, Gioti K, Kostomitsopoulos N, Papapetropoulos A, Tasouli A, Farmakis D, Davos CH, Klinakis A, Suter T, Cokkinos DV, Iliodromitis EK, Wenzel P, Andreadou I.
Efentakis P, et al. Among authors: gioti k.
Cardiovasc Res. 2020 Mar 1;116(3):576-591. doi: 10.1093/cvr/cvz163.
Cardiovasc Res. 2020.
PMID: 31228183